Detalhe da pesquisa
1.
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Ann Hematol
; 99(1): 105-112, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31776726
2.
CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial.
Lancet Haematol
; 5(5): e190-e200, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29703335